MAQS advises Vicore Pharma Holding in connection with listing on First North
Vicore Pharma develops pharmaceutical substances with action to the AT2 receptor and has added approximately 400 new shareholders in connection with the raising of capital through issuing new shares and IPO on First North. The total capital injection amounts to approximately SEK 25.5 million. The first day of trading for the listed shares was 10 December 2015.
MAQS has been the legal advisor to Vicore Pharma Holding (publ) in connection with the raising of capital and the IPO process. MAQS team consisted of Mikael Kowal and Wibeke Sorling.